Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
Published July 29, 2026 · Recall initiated: July 16, 2026
Summary
FDA records drug Class II recall D-0727-2026, published July 29, 2026 and initiated July 16, 2026. Recalling firm: Fresenius Kabi USA, LLC; Status: Ongoing; Reported quantity: 92,600 vials; Lot: Lot #: 6133436, Exp. Date 10/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Particulate Matter: Hair was found in products
What to do
Voluntary: Firm initiated · Letter
Get an email if NAROPIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- NAROPIN
- Manufacturer
- Fresenius Kabi USA, LLC
- Distributor
- Nationwide within in the USA
- UPC
- 0363323286033
- Lot
- Lot #: 6133436, Exp. Date 10/2028
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDALidocaine HCl Injection, USP, 2%, 100 mg per 5 mL (20 mg per mL), 25 Single Dose Vials, 5 mL per vial, RxJuly 29, 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL,July 29, 2026
- FDAGlycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only,July 29, 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL), 25 Multiple-Dose Vials, 50 mL,July 29, 2026
- FDARising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only, Manufactured for: RisingJuly 29, 2026
- FDACetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (AJuly 29, 2026
Questions about this recall
Was Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05 recalled?
Yes. FDA published recall D-0727-2026 on July 29, 2026. Reported hazard: Presence of Particulate Matter: Hair was found in products
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: NAROPIN. UPC: 0363323286033.